Huahui Health, BeOne Strike $2B HH160 Oncology Deal
BEIJING, CHINA, April 27, 2026 Huahui Health has announced a global exclusive option, license, and collaboration agreement with BeOne...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BEIJING, CHINA, April 27, 2026 Huahui Health has announced a global exclusive option, license, and collaboration agreement with BeOne...
FREDERICK, MARYLAND, April 30, 2026 Theradaptive has received U.S. Food and Drug Administration (FDA) authorization to advance its OASIS...
